Clinical Trial Update: A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating the safety, effectiveness, and pharmacokinetics of mirabegron in young children with neurogenic detrusor overactivity; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity

Drugs mentioned

• Myrbetriq (mirabegron)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Neurogenic Detrusor Overactivity | Phase 3 | Status: ACTIVE_NOT_RECRUITING